Respiratory Effects of Flow-Controlled Ventilation and Jet Ventilation in Patients Undergoing Laryngotracheal Surgery

Launched by UNIVERSITY HOSPITAL, GENEVA · Sep 25, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two different ways to help patients breathe during laryngotracheal surgery, which is a procedure involving the throat and voice box. The researchers want to compare "flow-controlled ventilation" and "high-frequency jet ventilation" to see how these methods affect lung function and breathing mechanics in patients who are under general anesthesia. Flow-controlled ventilation is a newer technique that allows doctors to manage breathing more effectively through a small breathing tube, which is often needed during this type of surgery.

To participate in this study, patients need to be adults over 18 years old who are scheduled for elective laryngotracheal surgery and can provide informed consent. However, individuals with certain severe heart, lung, or neurological conditions, or those who are obese, may not be eligible. Participants can expect to be monitored closely during the surgery to evaluate how well each ventilation method works. This trial is currently recruiting participants, and it aims to provide valuable insights into improving breathing support for patients undergoing these types of surgeries.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Informed Consent signed by the subject
• • General anesthesia for laryngotracheal surgery
• • Adult patients, female and male, over 18 years of age
• • Elective surgery
• Exclusion Criteria:
• • Documented severe heart conditions (New York Heart Association Class 4, severe pulmonary hypertension)
• • Documented severe respiratory disease (uncontrolled asthma, severe pulmonary fibrosis, chronic obstructive pulmonary disease GOLD 4)
• • Documented severe Neurological diseases (Acute ischemic and hemorrhagic stroke within the preceding 3 months, uncontrolled seizures)
• • Surgery that requires tracheotomy
• • Obesity (Body Mass Index ≥ 30 kg/m2)
• • Inability to follow the procedures of the study (mental condition or language barrier e.g. incomprehension of French language)
• • Previous enrolment into the current study or other study that involves unknown medication in the past 12 months
• • Allergy or contraindication to Propofol and/or Remifentanil and/or Rocuronium